1. Home
  2. EONR.WS vs GOVX Comparison

EONR.WS vs GOVX Comparison

Compare EONR.WS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EONR.WS

EON Resources Inc. Warrants each whole warrant exercisable for three quarters of one share of Class A Common Stock at an exercise price of $11.50 per whole share

N/A

Current Price

$0.04

Market Cap

2.8M

Sector

Energy

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$1.85

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EONR.WS
GOVX
Founded
N/A
2001
Country
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
EONR.WS
GOVX
Price
$0.04
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $240.00
AVG Volume (30 Days)
320.0
★ 286.6K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.07
$0.11
52 Week High
$0.07
$1,002.75

Technical Indicators

Market Signals
Indicator
EONR.WS
GOVX
Relative Strength Index (RSI) N/A 55.16
Support Level N/A $0.11
Resistance Level N/A $3.00
Average True Range (ATR) 0.00 0.31
MACD 0.00 0.30
Stochastic Oscillator 0.00 62.62

Price Performance

Historical Comparison
EONR.WS
GOVX

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: